About 1 million people are living with multiple sclerosis in the U.S., and about 10% of those have PPMS, making it the least common form of the disease.
BERLIN, Feb 7 () - Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug fenebrutinib ...
Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...
Roche's experimental drug fenebrutinib achieved significant results in a Phase III trial for primary progressive multiple sclerosis (PPMS), reducing the risk of disability progression by 12%. This ...
Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational ...
Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions ...
Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions ...
The court agreed on a block for early generics of a widely prescribed MS treatment, finding even though a psoriasis medication had similar compounds, the drug’s exclusivity clock had not yet run out.
Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and a trial for a different form of MS ...
Many women are diagnosed with multiple sclerosis (MS) at an age when they are considering starting a family. What does the disease and its medication mean for the child? To answer this question, a ...
An investigational drug for multiple sclerosis from Io Therapeutics has restored leg mobility and myelin nerve coatings in mice, the biotech announced Dec. 23. The Texas-based company conducted the ...
A Sanofi experimental drug for multiple sclerosis delayed disability progression in a late-stage trial, but failed to reduce episodes of new or worsening symptoms compared to an existing treatment in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results